ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Adaptive Biotechnologies statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Market Cap | $3.82B | $197.05M |
| Enterprise Value | $3.49B | $106.56M |
| PS Ratio | 12.41 | 3.93 |
| PB Ratio | 26.75 | 2.14 |
| P/TBV Ratio | 165.77 | 2.46 |
Enterprise value
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| EV / Sales | 11.31 | 2.69 |
Income (trailing twelve months)
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Revenue | $308.08M | $57.94M |
| Gross Profit | $232.83M | $90.47M |
| Operating Income | -$37.46M | -$21.44M |
| Net Income | -$63.85M | -$22.46M |
| EBITDA | -$37.46M | -$16.91M |
| EPS (Diluted) | -$0.41 | -$0.83 |
Margins
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Gross Margin | 75.6% | 52.3% |
| Operating Margin | -12.2% | -44.5% |
| Profit Margin | -20.7% | -39.2% |
| EBITDA Margin | -12.2% | -31.3% |
| FCF Margin | -7.80% | -8.85% |
Returns
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.6% | -53.1% |
| Return on Assets (ROA) | -11.2% | -41.0% |
| Return on Capital Employed (ROCE) | -6.77% | -37.8% |
Growth
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 50.1% | 6.01% |
| Revenue Growth (3Y CAGR) | 14.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 23.0% | 6.42% |
Balance sheet
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $344.26M | $62.42M |
| Total Debt | $0 | $120.13M |
| Net Cash (Debt) | $344.26M | $15.68M |
| Net Cash Per Share | $2.16 | $0.65 |
| Equity (Book Value) | $142.91M | $48.79M |
| Book Value Per Share | $0.90 | $1.36 |
| Tangible Book Value | $23.06M | $23.06M |
| Working Capital | $332.85M | $75.77M |
Financial position
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Current Ratio | 4.79 | 3.30 |
| Quick Ratio | 4.49 | 2.39 |
| Debt / Equity | 0.00 | 0.51 |
| Interest Coverage | -3.26 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Operating Cash Flow | -$21.01M | -$12.35M |
| Capital Expenditures | -$3.03M | -$1.06M |
| Free Cash Flow | -$24.03M | -$20.28M |
| FCF Per Share | -$0.15 | -$0.41 |
Efficiency
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Asset Turnover | 0.54 | 0.38 |
| Inventory Turnover | 7.96 | 2.67 |
| Revenue Per Employee | $493.72K | $398.96K |
| Profits Per Employee | -$102.33K | -$732.08K |
| Employee Count | 624 | 73 |
Dividends and yields
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Earnings Yield | -1.67% | -21.2% |
| FCF Yield | -0.63% | -7.64% |
Shares
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Shares Outstanding | 159,596,000 | 59,128,900 |
| Shares Change (YoY) | 5.90% | 11.1% |
| Shares Change (QoQ) | -0.40% | 0.54% |
| Float | 123,169,000 | 48,744,500 |
| Shares Held by Insiders | 22.8% | 11.8% |
| Shares Held by Institutions | 97.6% | 59.4% |
Scores
| Measure | Adaptive Biotechnologies | Industry median |
|---|---|---|
| Altman Z-Score | 2.48 | 0.10 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -2.42 | -2.62 |
Calculated by StockData from Adaptive Biotechnologies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.